Mohammad leads the strategic direction of the fund, leveraging his extensive experience in life sciences investments. He works closely with NG Bio’s limited partners and co-investors to maximise the potential of our investments. Mohammad is particularly adept at forging strategic partnerships with major pharmaceutical companies and funds, regularly collaborating with them to share deal flow and align on growth opportunities.

Mohammad is also deeply involved in guiding our companies through their financing strategies, helping them navigate the complexities of growth and exit planning from the very beginning. His hands-on approach ensures that our portfolio companies are well-positioned for success in the highly competitive biotech landscape.

Before co-founding NG Bio, Mohammad was a key life science investor at a family office, where he successfully founded and led the expansion of their life sciences strategy. Under his leadership, the portfolio achieved an impressive track record of over 3.5x returns in just six years. His responsibilities encompassed deal sourcing, due diligence, growth strategy, and exit planning. He also played a pivotal role as an Investment Committee member and served on the boards of several portfolio companies, where his insights and guidance were instrumental in driving value.

Jason leads venture creation at NG Bio alongside overseeing the day to day operations at NG Bio. He is an active board member and observer for a number of companies in the current portfolio. Alongside the team, Jason has built three companies and led/co-led multiple investment rounds, including as the lead for NG Bio’s investment in Cellesce which was soon after acquired by Danaher.

Jason has worked with entrepreneurs across the life sciences as an advisor and angel investor for over five years. Before starting NG Bio, he helped founders in the biotech and mental health space go from ideation to funding and beyond. Prior to his entrepreneurial experience, Jason worked for EY in London and Tokyo, supporting Japanese biotechs and MNEs with restructuring, M&A and compliance.

He holds an MBA from London Business School, is a Certified Chartered Accountant, and earned a first-class degree in mechanical engineering.

Tim is responsible for NG Bio’s approach to therapeutic development. Working closely with our network of industry boards, CROs, and KOLs, Tim assesses the pharmaceutical technology and its therapeutic potential, and then formulates the right plans for each therapeutic venture. Using the latest techniques to de-risk and optimise development, Tim supports each of our founders navigate the often tricky process of translation.

Before joining NG Bio, Tim previously worked as a Director of Autoimmune Research at Imcheck Therapeutics, Associate Director of Discovery at VHsquared, and Consultant Project Manager of Drug Development at LeanPharma. Throughout these roles, he completed several successful drug discovery programmes in inflammatory intestinal diseases, managed the preclinical development of a CNS-active small molecule drug, and devised drug development plans for novel autoimmune therapies. Before finding his passion in drug development, Tim worked as a trainee patent attorney at a prestigious London firm.

Tim has a PhD in Microbial Genetics from the University of Otago and completed a postdoctoral position at the University of Cambridge working on pathogenic bacteria. He translated these skills into the industry in the first position to treat bacteria-induced inflammation in GI disease.

When not cooking and discovering new cuisines, Tim can be found in the outdoors pursuing his favourite sports of mountain biking and snowboarding.

What does Tim bring to NG Bio?
Tim is known for his analytical thinking and loves nothing more than getting into the weeds on a topic. He uses these skills to help his team members achieve their goals, motivating them to problem-solve and express themselves freely.

Neil is an Immunopharmacologist providing advice & expertise to support preclinical drug discovery projects in inflammatory & autoimmune diseases. He has over 30 years’ experience in the discovery & development of novel therapeutics at UCB-Celltech.

Significant contribution to UCB’s drug discovery research pipeline being instrumental for progression of 3 biological and 3 small molecule projects into clinical studies. He was also involved in the in-licensing of 2 early clinical candidates for the treatment of Fibrosis & Type 1 diabetes from academia.

He has performed numerous roles within pre-clinical research including group leader, project leadership, new target strategy, portfolio management, translational research, in-licencing and external collaborations. Most recent role was Senior Director of New Targets & Scouting to create a research pipeline of high value differentiated medicines from internal and external sources. External opportunities ranging from new targets to phase 2B drug candidates are identified from academic groups and biotech companies for internal assessment.

Over the past 15 years he reviewed and triaged hundreds of in-licensing project applications.

Ted is a consultant to international pharmaceutical and biopharmaceutical research and development, with 30 years’ experience in drug metabolism, bioanalysis, pharmacokinetics, pharmacodynamics and safety evaluation, from concept to post-marketing support. With a BA in Natural Sciences (Chemistry) from Cambridge and a PhD in natural product chemistry from Southampton, he has broad knowledge of a wide variety of technologies.

In eight years at Upjohn and 21 years at Celltech/UCB, he worked in most therapeutic areas and gained insight into many of the difficulties that patients, scientists, clinicians and executives face. He has worked on small molecule and biologic projects. He is first author on a patent for a kinase inhibitor in development (seletalisib) and has extensive experience of the in vivo properties of high molecular weight PEG. Through his involvement in Due Diligence for both in-licensing and out-licensing projects, he has investigated and assessed many technological developments.

John is an experienced pharmaceutical and biotech physician with a track-record of success in building organisations and leading and managing product development programmes. His 25 year career has spanned multiple large pharmaceutical companies such as Wyeth and Novartis and smaller biotech organisations such as Veloxis, 4D Pharma, Enzon and MaaT, with roles in both the USA and Europe. John has been responsible for the development and launch of many drugs in the fields of immunology, oncology and transplantation.

John qualified as a medical doctor at the University of the Witwatersrand in Johannesburg and practiced cardiology at Baragwanath Hospital before obtaining an MBA from INSEAD in France.

Chris is responsible for leading Autolus’ business development activities. Prior to Autolus he served as a senior business manager at UCL Business where he developed extensive experience in early stage technology commercialisation of academic technologies including licensing, strategic partnerships, fund raising and company formation.

Chris has held non-executive directorships at Autolus and Orchard Therapeutics, two of the UCL spinout companies he founded during his tenure at UCL Business.

Previously Chris has held BD positions in UK biotech (Thiologics and Canbex) and for large pharma (Eli Lilly). Before moving into BD, Chris worked as a research scientist in industry (GSK and Inpharmatica) and academia (Imperial).

Chris holds a PhD in Biochemistry from Imperial College London, and worked as a Postdoctoral scientist in the MRC Lymphocyte Development group also based at Imperial College London.

Adel Nada is biotech executive and serial entrepreneur. Currently, he advises several funds on new venture creation and is co-founder and executive chairman of Trutina and FytonBio, two early-stage companies in the immunology and inflammation space. Previously, Adel cofounded and was CEO of GentiBio, a biotherapeutics company developing engineered regulatory T cells programmed to treat autoimmune and inflammatory diseases. Adel led GentiBio through two rounds of equity financing and the first transformative deal with large pharma in the Treg space. Prior to GentiBio, Adel was the Chief Medical Officer of Casebia Therapeutics where he worked on advancing engineered regulatory T cell (Tregs) therapeutics. In the past, Adel has held executive positions in various biotech and pharmaceutical companies, including Vice President at Intellia Therapeutics and Caladrius Biosciences, and various senior positions directing clinical development at Baxter and Abbott. He successfully led translational and immunology programs over past 15 years for experimental and approved therapies, spanning small and large molecules and engineered immune cell products, including Tregs products. Adel received his medical degree from Alexandria University in Egypt and his master’s degree in clinical research from the Pharmacology Dept. at Rush University in Chicago where he also held an academic position. Adel completed advanced studies in drug development at UCSF and University of Basel before becoming a Member of the Faculty of Pharmaceutical Medicine in the UK. Prior to joining the industry, Adel trained in surgery and internal medicine and practiced for 10 years in Chicago